Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

946
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
946
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

759
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
759
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.4K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.4K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

1.2K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.2K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

2.9K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological Interventions for Hereditary Transthyretin-Related Amyloidosis With Polyneuropathy: Systematic Review and Network Meta-Analysis.

European journal of neurology·2026
Same author

Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Large scale functional and effective connectivity alterations cross the Huntington's disease integrated staging system.

NeuroImage. Clinical·2026
Same author

Recurrent pregnancy loss: systematic review and meta-analysis of overall prevalence and the distribution of major etiological categories.

Frontiers in medicine·2026
Same author

A clinimetric evaluation of the problem behaviors assessment short form (PBA-s) within the context of the Huntington's disease integrated staging system (HD-ISS).

Journal of Huntington's disease·2026
Same author

From genes to trajectories: mapping genetic influences on Huntington's disease progression.

Bioinformatics (Oxford, England)·2026

Related Experiment Video

Updated: Nov 29, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

24.0K

Botulinum toxin type A therapy for blepharospasm.

Gonçalo S Duarte1,2, Filipe B Rodrigues1,2, Raquel E Marques2,3

  • 1Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal.

The Cochrane Database of Systematic Reviews
|November 19, 2020
PubMed
Summary
This summary is machine-generated.

Botulinum toxin type A (BtA) effectively reduces blepharospasm severity and disability in the short term. While generally safe, it may increase risks of vision complaints and eyelid ptosis, with limited data on long-term effects.

More Related Videos

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.3K
A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.6K

Related Experiment Videos

Last Updated: Nov 29, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

24.0K
Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
12:25

Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays

Published on: March 3, 2014

16.3K
A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

5.6K

Area of Science:

  • Neurology
  • Ophthalmology
  • Pharmacology

Background:

  • Blepharospasm is a common focal dystonia causing involuntary eyelid closure.
  • Botulinum toxin type A (BtA) is the primary treatment for blepharospasm.
  • This review updates evidence on BtA efficacy and safety.

Purpose of the Study:

  • To compare the efficacy, safety, and tolerability of BtA versus placebo for blepharospasm.
  • To assess the impact of BtA on symptom severity and disability.

Main Methods:

  • Systematic review of three double-blind, randomized, placebo-controlled trials (RCTs).
  • Meta-analysis of outcomes including symptom severity, disability, and adverse events.
  • Searches conducted in July 2020 across multiple databases without language restrictions.

Main Results:

  • BtA significantly improved blepharospasm severity and disability compared to placebo at 4-6 weeks post-injection.
  • No increased risk of overall adverse events was observed.
  • Increased risks of vision complaints and eyelid ptosis were associated with BtA treatment.

Conclusions:

  • Moderate certainty exists that BtA provides clinically relevant short-term benefits for blepharospasm.
  • Low certainty surrounds BtA's tolerability, with likely increased risks of specific adverse events.
  • Further RCTs are needed to evaluate repeated BtA cycles, optimal dosing, and quality of life impacts.